Related Experiment Video
Updated: Nov 4, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
The economic burden of pneumonia in children under five in Uganda
Elizabeth Ekirapa-Kiracho1, Gatien De Broucker2, Anthony Ssebagereka1
1Makerere University School of Public Health, Uganda.
Insights
Pneumonia treatment incurs significant household costs in Uganda, with nearly 40% of families facing catastrophic expenditures. Understanding these economic impacts is crucial for public health interventions.
Area of Science:
- Public Health
- Health Economics
- Epidemiology
Background:
- Pneumonia causes millions of deaths globally and is a leading cause of child mortality in Uganda.
- The economic burden of pneumonia on households and caregivers is not well-documented.
Purpose of the Study:
- To estimate the economic costs of a pneumonia episode from household, government, and societal perspectives in Uganda.
Main Methods:
- A cost-of-illness study was conducted using an ingredient-based approach.
- Data were collected from 48 healthcare facilities across public and private sectors.
- Household costs included direct (medical, non-medical) and indirect (human capital approach) costs.
Main Results:
- The average societal cost per pneumonia episode was $42, with hospitalized cases costing $62 and ambulatory cases $16.
- Public healthcare facilities incurred lower costs ($12 hospitalized, $7 ambulatory) compared to private facilities.
- Approximately 39% of households experienced catastrophic health expenditures due to pneumonia treatment costs.
Conclusions:
- Pneumonia treatment imposes a substantial economic burden on households in Uganda.
- Caregiver out-of-pocket payments vary significantly across public and private healthcare sectors.
- Findings highlight the need for financial protection strategies to mitigate the economic impact of pneumonia.
Background:
There were about 138 million new episodes of pneumonia and 0.9 million deaths globally in 2015. In Uganda, pneumonia was the fourth leading cause of death in children under five years of age in 2017-18. However, the economic burden of pneumonia, particularly for households and caregivers, is poorly documented.
Aim:
To estimate the costs associated with an episode of pneumonia from the household, government, and societal perspectives.
Methods:
We selected 48 healthcare facilities from the public and private sector across all care levels (primary, secondary, and tertiary), based on the number of pneumonia episodes reported for 2015-16. Adult caregivers of children with pneumonia diagnosis at discharge were selected. Using an ingredient-based approach, we collected cost and utilization data from administrative databases, medical records, and patient caregiver surveys. Household costs included direct medical and non-medical costs, as well as indirect costs estimated through a human capital approach. All costs are presented in 2018 U.S. dollars.
Results:
The treatment of pneumonia puts a substantial economic burden on households. The average societal cost per episode of pneumonia across all sectors and types of visits was $42; hospitalized episodes costed an average of $62 per episode, while episodes only requiring ambulatory care was $16 per episode. Public healthcare facilities covered $12 and $7 on average per hospitalized or ambulatory episode, respectively. Caregivers using the public system faced lower out-of-pocket payments, evaluated at $17, than those who used private for-profit ($21) and not-for-profit ($50) for hospitalized care. For ambulatory care, out-of-pocket payments amounted to $8, $18, and $9 for public, private for-profit, and not-for-profit healthcare facilities, respectively. About 39% of households experienced catastrophic health expenditures due to out-of-pocket payments related to the treatment of pneumonia.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...